SCHEDULE 13D/A: Major Shareholder Charles Cherington Boosts Stake in Eterna Therapeutics to 32.38% Through Debt and Warrant Conversions
Beneficial Ownership Update
Charles Cherington, a significant investor, has increased his beneficial ownership in Eterna Therapeutics Inc. to 32.38% through a series of strategic debt and warrant conversions and exchanges.
Summary
- Charles Cherington now beneficially owns 16,642,183 shares of Eterna Therapeutics Inc. Common Stock, representing 32.38% of the outstanding class.
- This ownership includes 16,628,123 shares of Common Stock and 14,060 shares issuable upon conversion of Series A convertible preferred stock.
- The percentage is calculated based on 51,388,773 total outstanding shares of Common Stock, including those convertible within 60 days.
- On September 23, 2024, Mr. Cherington acquired rights to $240,000 in 6.0% Senior Convertible Promissory Notes due 2028 and 167,832 warrants by forgiving $100,000 in personal loans to two investors.
- On October 29, 2024, he acquired $1,368,626 in 12% Senior Convertible Notes due September 24, 2025 and 5,474,504 accompanying warrants from the Issuer in a private placement.
- Concurrently on October 29, 2024, Mr. Cherington consummated a Warrant Exchange, converting various warrants (2022, July 2023, December 2023, Assigned, and 2024 Warrants) into 4,310,463 shares of Common Stock at an exchange ratio of 0.5 shares per warrant.
- Also on October 29, 2024, a Notes Exchange occurred, converting $3.54 million in 6.0% Notes and $3.0 million in 12.0% Notes into 8,941,649 shares of Common Stock.
- The Notes Exchange conversion ratio was based on the principal amount plus accrued and future interest divided by $1.00.
- Simultaneously, the $1,368,626 in 2025 Notes plus accrued interest were automatically converted into 2,819,546 shares of Common Stock at a conversion price of $0.50 per share.
- In total, the Exchange Transactions and Notes Conversion resulted in the acquisition of 16,071,658 shares of Common Stock by Mr. Cherington.
- These transactions were approved by Eterna Therapeutics' stockholders at the Annual Meeting on October 29, 2024.
Sentiment
Score: 7
Explanation: The significant increase in a major shareholder's stake, coupled with the conversion of substantial debt into equity, generally signals confidence from a key insider and a strengthening of the company's balance sheet, despite the associated dilution.
Positives
- Significant increase in beneficial ownership by a key investor (Charles Cherington) to 32.38%, indicating strong confidence in the company.
- Conversion of substantial debt ($3.54 million in 6.0% Notes, $3.0 million in 12.0% Notes, and $1.368 million in 2025 Notes) into equity, which can strengthen the company's balance sheet by reducing liabilities.
- Simplification of the capital structure by converting various warrants and convertible notes into common stock.
Negatives
- The conversion of debt and warrants into common stock results in dilution for existing shareholders, as the number of outstanding shares increases.
- The conversion price of $0.50 per share for the 2025 Notes may be considered low, potentially indicating a valuation at the time of conversion.
Future Outlook
The filing states that the Reporting Person has no present plan or proposal that relates to, or could result in, any of the events typically outlined in Item 4 of Schedule 13D, such as mergers, liquidations, or major changes to the Issuer's business or corporate structure.
Industry Context
This Schedule 13D filing primarily details a change in beneficial ownership and capital restructuring by a major shareholder, Charles Cherington, within Eterna Therapeutics Inc. It does not provide broader industry trends or competitive analysis.
Related Party Transactions
- On September 23, 2024, the Reporting Person acquired rights to $240,000 in 2028 Notes and 167,832 warrants in exchange for forgiving $100,000 in personal loans to two investors. While not explicitly labeled as related party by the Issuer, this transaction involves the Reporting Person and other investors.
Stakeholder Impact
- Shareholders: Experience dilution due to the issuance of new common stock from debt and warrant conversions, but also benefit from increased insider ownership and a potentially stronger balance sheet.
- Creditors: The conversion of convertible notes into equity reduces the company's debt obligations, potentially improving its credit profile.
Key Dates
| Date | Description |
|---|---|
| 2021-05-13 | Original Schedule 13D filed with the SEC. |
| 2022-03-16 | Amendment No. 1 to Schedule 13D filed. |
| 2022-12-14 | Amendment No. 2 to Schedule 13D filed. |
| 2022-12-01 | Warrants to purchase 261,756 shares of Common Stock issued (2022 Warrants). |
| 2023-07-01 | Warrants to purchase 1,153,846 shares of Common Stock issued (July 2023 Warrants). |
| 2023-09-07 | Amendment No. 3 to Schedule 13D filed. |
| 2023-12-01 | Warrants to purchase 1,562,988 shares of Common Stock issued (December 2023 Warrants). |
| 2023-12-20 | Amendment No. 4 to Schedule 13D filed. |
| 2024-09-23 | Reporting Person acquired rights to $240,000 in 2028 Notes and 167,832 Assigned Warrants by forgiving personal loans. |
| 2024-09-24 | Date of Securities Purchase Agreement for the acquisition of 2025 Notes and 2024 Warrants. |
| 2024-10-29 | Date of event requiring filing of this statement; Reporting Person acquired 2025 Notes and 2024 Warrants in private placement; Warrant Exchange, Notes Exchange, and Notes Conversion consummated; Issuer's Annual Meeting of Stockholders where transactions were approved. |
| 2024-11-12 | Date as of which 51,374,713 shares of common stock were outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q. |
| 2025-02-18 | Date as of which the Reporting Person's beneficial ownership is stated. |
| 2025-03-05 | Date of signature for this Amendment No. 5 to Schedule 13D. |
Recommendation
holdKeywords
Eterna Therapeutics Inc., Charles Cherington, Beneficial Ownership, Schedule 13D, Common Stock, Convertible Notes, Warrants, Debt Conversion, Equity Conversion, Private Placement, Capital Restructuring, Shareholder Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.